GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
Rhea-AI Summary
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024). The event will take place from October 12-16, 2024, in Athens, Greece.
The company's abstract has been accepted for a poster presentation titled "Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis." Dr. Vipin Kumar Chaturvedi, GRI Bio's Chief Scientific Officer, will present the poster (Number PP 184) on Tuesday, October 15, 2024, from 3:30 PM to 5:00 PM EEST.
This presentation highlights GRI Bio's ongoing research in the field of lung fibrosis and demonstrates the company's commitment to advancing its innovative pipeline of NKT cell modulators for treating various diseases.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GRI declined 3.24%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LA JOLLA, CA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024) being held October 12-16, 2024 in Athens, Greece.
Details of the poster presentation are as follows:
Title: Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis
Presenter: Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio
Poster Number: PP 184
Date and Time: Tuesday, October 15, 2024, 3:30 PM – 5:00 PM EEST
For more information about the event, please visit the conference website here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
What is GRI Bio presenting at ICLAF 2024?
When and where is GRI Bio's poster presentation at ICLAF 2024?
Who is presenting GRI Bio's research at ICLAF 2024?
What is the focus of GRI Bio's research presented at ICLAF 2024?
What is GRI Bio's stock symbol?
